Pharmacogenetics Research Clinic


Canadian Biomarker Integration Network for Depression (CAN-BIND) is a national, multi-site study involving researchers at eight Canadian universities (University of Toronto, McMaster University, Queen’s University, University of Guelph, University of Ottawa, McGill University, University of Calgary, and University of British Columbia), in addition to collaborations with the Ontario Cancer Biomarker Network and the Ontario Brain Institute.

The main goal of CAN-BIND is to identify biomarkers of major depressive disorder (MDD) with the intent of improving the accuracy and efficiency of diagnosis, and informing treatment selection. Bioinformatics will be used to integrate biomarker data across clinical, imaging, and molecular modalities. CAN-BIND-1 is the first tier of the project, and it will identify biomarkers of treatment response to pharmacotherapy in MDD. The scope of CAN-BIND will eventually expand to include depression in other populations, and other treatment types such as neurostimulation. For more information on CAN-BIND, please refer to website.
Watch offcial CAN-BIND video: